Eye Meds Now

 Quick Ophthalmic Drug Search

231 items found
TYLENOL REGULAR STRENGTH (acetaminophen (325 mg) tablets; (325 mg) capsules)
Over the Counter
Oral
Capsules
Tablets
Acetaminophen
Indications/Usage:

Temporarily relieves minor aches and pains and temporarily reduces fever.


Typical Dosing:  

Minor aches and pains or fever:

  • Do not take more than directed (see overdose warning in package insert).
  • Adults and children  12 years of age:
    • Take 2 tablets or capsules every 4 – 6 hours while symptoms last.
    • Do not take > 10 tablets or capsules in 24 hours, unless directed by a doctor.
    • Do not use for > 10 days unless directed by a doctor.
  • Children 6 years to < 12 years:
    • Take 1 tablet or capsule every 4 – 6 hours while symptoms last.
    • Do not take > 5 tablets or capsules in 24 hours, unless directed by a doctor.
    • Do not use for > 5 days unless directed by a doctor.
  • Children < 6 years:
    • Ask a doctor.

How Supplied:  
  • 325 mg capsules
  • 325 mg tablets

Preservatives:  

None listed in package insert.


Storage:  
  • Store between 68° – 77°F (20° – 25°C).


TYLENOL WITH CODEINE (acetaminophen (300 mg) – codeine phosphate (30 mg; 60 mg) tablets)
Opioid
Prescription
Oral
Tablets
Opiates/Opioids
Indications/Usage:

Indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate.

Limitations of Use

Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses (See WARNINGS in package insert), reserve TYLENOL® with Codeine tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]

  • Have not provided adequate analgesia, or are not expected to provide adequate analgesia.
  • Have not been tolerated, or are not expected to be tolerated.

Typical Dosing:  

Mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate:

  • Initial dosage:
    • Dosage should be adjusted according to severity of pain and response of the patient. However, it should be kept in mind that tolerance to codeine can develop with continued use and that the incidence of untoward effects is dose related.
    • Adult doses of codeine higher than 60 mg are associated with an increased incidence of adverse reactions and are not associated with greater efficacy.
    • The usual adult dosage is:
      • TYLENOL with Codeine No. 3 tablets (codeine 30 mg and acetaminophen 300 mg):
        • Take 1 – 2 tablets every 4 hours as needed for pain.
      • TYLENOL with Codeine No. 4 tablets (codeine 60 mg and acetaminophen 300 mg):
        • Take 1 tablet every 4 hours as needed for pain.
    • The prescriber must determine the number of tablets per dose, and the maximum number of tablets per 24 hours, based upon the following dosage guidance. This information should be conveyed in the prescription.
      • Codeine phosphate:
        • Single Doses (Range): 30 – 60 mg. 
        • Maximum 24-hour Dose: 350 mg.
      • Acetaminophen:
        • Single Doses (Range): 300 mg – 1,000 mg.
        • Maximum 24-hour Dose: 4,000 mg.
    • Conversion from other opioids: There is inter-patient variability in the potency of opioid drugs and opioid formulations. Therefore, a conservative approach is advised when determining the total daily dosage of TYLENOL with Codeine tablets. It is safer to underestimate a patient's 24-hour TYLENOL with Codeine tablets dosage than to overestimate the 24-hour TYLENOL with Codeine tablets dosage and manage an adverse reaction due to overdose.
  • Titration and maintenance of therapy:
    • Individually titrate TYLENOL with Codeine tablets to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving TYLENOL with Codeine tablets to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse (See WARNINGS in package insert). Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.
    • If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the TYLENOL with Codeine tablets dosage. If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.
  • Safe reduction or discontinuation of TYLENOL with Codeine:
    • Do not abruptly discontinue TYLENOL with Codeine tablets in patients who may be physically dependent on opioids. Rapid discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.
    • When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking TYLENOL with Codeine tablets, there are a variety of factors that should be considered, including the dose of TYLENOL with Codeine the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. It is important to ensure ongoing care of the patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic. When opioid analgesics are being discontinued due to a suspected substance use disorder, evaluate and treat the patient, or refer for evaluation and treatment of the substance use disorder. Treatment should include evidence-based approaches, such as medication assisted treatment of opioid use disorder. Complex patients with comorbid pain and substance use disorders may benefit from referral to a specialist.
    • There are no standard opioid tapering schedules that are suitable for all patients. Good clinical practice dictates a patient-specific plan to taper the dose of the opioid gradually. For patients on TYLENOL with Codeine tablets who are physically opioid-dependent, initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks. Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper.
    • It may be necessary to provide the patient with lower dosage strengths to accomplish a successful taper. Reassess the patient frequently to manage pain and withdrawal symptoms, should they emerge. Common withdrawal symptoms include restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. If withdrawal symptoms arise, it may be necessary to pause the taper for a period of time or raise the dose of the opioid analgesic to the previous dose, and then proceed with a slower taper. In addition, monitor patients for any changes in mood, emergence of suicidal thoughts, or use of other substances.
    • When managing patients taking opioid analgesics, particularly those who have been treated for a long duration and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper. A multimodal approach to pain management may optimize the treatment of chronic pain, as well as assist with the successful tapering of the opioid analgesic (See WARNINGS/Withdrawal, DRUG ABUSE AND DEPENDENCE in package insert).
  • Additional important Dosage and Administration instructions in Notes below.

How Supplied:  
  • Tylenol with Codeine No. 3 tablets:
    • 300 mg acetaminophen – 30 mg codeine phosphate per tablet
  • Tylenol with Codeine No. 4 tablets:
    • 300 mg acetaminophen – 60 mg codeine phosphate per tablet

Preservatives:  

sodium metabisulfite


Storage:  
  • Store at 68° – 77°F (20° – 25°C).


ULTRACET (tramadol hydrochloride (37.5 mg) – acetaminophen (325 mg) tablets)
Opioid
Prescription
Oral
Tablets
Opiates/Opioids
Indications/Usage:

Indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Limitations of Use:

ULTRACET tablets are indicated for short-term use of 5 days or less.

Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [See Warnings and Precautions (5.1) in package insert], reserve ULTRACET for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]:

  • Have not been tolerated, or are not expected to be tolerated.
  • Have not provided adequate analgesia, or are not expected to provide adequate analgesia.
This medication has a broad FDA approval for "pain severe enough to require an opioid analgesic." Under our interpretation of this indication we have linked this medication with conditions we understand may be associated with "pain severe enough to require an opioid analgesic." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate, recommended:

  • Initial dosage:
    • 2 tablets every 4 – 6 hours as needed for pain relief up to a maximum of 8 tablets per day.
  • Dosage modification in patients with renal impairment:
    • In patients with CrCl < 30 mL/min, do not exceed 2 tablets every 12 hours.
  • Safe reduction or discontinuation of ULTRACET:
    • Do not abruptly discontinue ULTRACET in patients who may be physically dependent on opioids. Rapid discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.
    • When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking ULTRACET, there are a variety of factors that should be considered, including the dose of ULTRACET the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. It is important to ensure ongoing care of the patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic. When opioid analgesics are being discontinued due to a suspected substance use disorder, evaluate and treat the patient, or refer for evaluation and treatment of the substance use disorder. Treatment should include evidence-based approaches, such as medication assisted treatment of opioid use disorder. Complex patients with comorbid pain and substance use disorders may benefit from referral to a specialist.
    • There are no standard opioid tapering schedules that are suitable for all patients. Good clinical practice dictates a patient-specific plan to taper the dose of the opioid gradually. For patients on opioids who are physically opioid-dependent, initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and use a gradual downward taper. Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper.
    • It may be necessary to provide the patient with lower dosage strengths to accomplish a successful taper. Reassess the patient frequently to manage pain and withdrawal symptoms, should they emerge. Common withdrawal symptoms include restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. If withdrawal symptoms arise, it may be necessary to pause the taper for a period of time or raise the dose of the opioid analgesic to the previous dose, and then proceed with a slower taper. In addition, monitor patients for any changes in mood, emergence of suicidal thoughts, or use of other substances.
    • When managing patients taking opioid analgesics, particularly those who have been treated for a long duration and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper. A multimodal approach to pain management may optimize the treatment of chronic pain, as well as assist with the successful tapering of the opioid analgesic [See Warnings and Precautions (5.20), Drug Abuse and Dependence (9.3).
  • Additional important Dosage and Administration instructions in Notes below.

How Supplied:  
  • 325 mg acetaminophen and 37.5 mg tramadol hydrochloride tablets

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Excursions permitted to 59° – 86° F (15° – 30°C).
  • Store securely and dispose of properly [See Patient Counseling Information (17) in package insert].


ULTRAM (tramadol hydrochloride (50 mg) tablets)
Opioid
Prescription
Oral
Tablets
Opiates/Opioids
Indications/Usage:

Indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Limitations of Use:

Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [See Warnings and Precautions (5.1) in package insert], reserve ULTRAM for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]:

  • Have not been tolerated or are not expected to be tolerated.
  • Have not provided adequate analgesia or are not expected to provide adequate analgesia.
This medication has a broad FDA approval for "pain severe enough to require an opioid analgesic." Under our interpretation of this indication we have linked this medication with conditions we understand may be associated with "pain severe enough to require an opioid analgesic." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate:

  • Initial adult dosage:
    • For patients not requiring rapid onset of analgesic effect, the tolerability of ULTRAM® can be improved by initiating therapy with the following titration regimen:
      • Start ULTRAM® at 25 mg/day and titrate in 25 mg increments as separate doses every 3 days to reach 100 mg/day (25 mg four times a day).
      • Thereafter the total daily dose may be increased by 50 mg as tolerated every 3 days to reach 200 mg/day (50 mg four times a day).
      • After titration, ULTRAM® 50 – 100 mg can be administered as needed for pain relief every 4 – 6 hours not to exceed 400 mg/day.
    • For the subset of patients for whom rapid onset of analgesic effect is required and for whom the benefits outweigh the risk of discontinuation due to adverse events associated with higher initial doses, ULTRAM® 50 mg – 100 mg can be administered as needed for pain relief every 4 – 6 hours, not to exceed 400 mg per day.
  • Conversion to extended-release tramadol:
    • The relative bioavailability of ULTRAM® compared to extended-release tramadol is unknown, so conversion to extended-release formulations must be accompanied by close observation for signs of excessive sedation and respiratory depression.
  • Dosage modification in patients with hepatic impairment:
    • The recommended dose for adult patients with severe hepatic impairment is 50 mg every 12 hours.
  • Dosage modification in patients with renal impairment:
    • In all patients with CrCl < 30 mL/min, it is recommended that the dosing interval of ULTRAM® be increased to 12 hours, with a maximum daily dose of 200 mg. Since only 7% of an administered dose is removed by hemodialysis, dialysis patients can receive their regular dose on the day of dialysis.
  • Dosage modification in geriatric patients:
    • Do not exceed a total dose of 300 mg/day in patients over 75 years old.
  • Titration and maintenance of therapy:
    • Individually titrate ULTRAM® to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving ULTRAM® to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as to monitor for the development of addiction, abuse, or misuse [See Warnings and Precautions (5.1) in package insert]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.
    • If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the ULTRAM® dosage. If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.
  • Safe reduction or discontinuation of ULTRAM®:
    • Do not abruptly discontinue ULTRAM® in patients who may be physically dependent on opioids. Rapid discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drugseeking for abuse. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.
    • When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking ULTRAM®, there are a variety of factors that should be considered, including the dose of ULTRAM® the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. It is important to ensure ongoing care of the patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic. When opioid analgesics are being discontinued due to a suspected substance use disorder, evaluate and treat the patient, or refer for evaluation and treatment of the substance use disorder. Treatment should include evidence-based approaches, such as medication assisted treatment of opioid use disorder. Complex patients with comorbid pain and substance use disorders may benefit from referral to a specialist.
    • There are no standard opioid tapering schedules that are suitable for all patients. Good clinical practice dictates a patient-specific plan to taper the dose of the opioid gradually. For patients on ULTRAM® who are physically opioid-dependent, initiate the taper by a small enough increment, (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks. Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper.
    • It may be necessary to provide the patient with a lower dosage strength to accomplish a successful taper. Reassess the patient frequently to manage pain and withdrawal symptoms, should they emerge.Common withdrawal symptoms include restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. If withdrawal symptoms arise, it may be necessary to pause the taper for a period of time or raise the dose of the opioid analgesic to the previous dose, and then proceed with a slower taper. In addition, monitor patients for any changes in mood, emergence of suicidal thoughts, or use of other substances.
    • When managing patients taking opioid analgesics, particularly those who have been treated for a long duration and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper. A multimodal approach to pain management may optimize the treatment of chronic pain, as well as assist with the successful tapering of the opioid analgesic [See Warnings and Precautions (5.17), Drug Abuse and Dependence (9.3) in package insert].
  • Additional information for Dosage and Administration is in Notes below.

How Supplied:  
  • 50 mg tablets

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Excursions permitted to 59 – 86°F (15° –  30°C).
  • Store securely and dispose of properly [See Patient Counseling Information (17) in package insert].


VALACYCLOVIR (valacyclovir hydrochloride (500 mg; 1 g) tablets)
Prescription
Oral
Tablets
Antivirals
Indications/Usage:

For adult patients, indicated for the treatment of herpes zoster (shingles) in immunocompetent adults. The efficacy of valacyclovir when initiated more than 72 hours after the onset of rash and the efficacy and safety of valacyclovir for treatment of disseminated herpes zoster have not been established.

The efficacy and safety of valacyclovir have not been established in patients 18 years of age with herpes zoster.


Typical Dosing:  

Herpes zoster (shingles) in immunocompetent adults, recommended:

  • 1 g 3 times daily for 7 days. Therapy should be initiated at the earliest sign or symptom of herpes zoster and is most effective when started within 48 hours of the onset of rash.

Herpes simplex keratitis (acute) in immunocompetent adults, recommended:

  • 500 mg 3 times daily for 7 – 10 days.

Herpes simplex keratitis (prophylaxis) in immunocompetent adults, recommended:

  • 500 mg daily for 1 year as prophylaxis against a simplex recurrence after recurrent bouts of keratitis.

Additional information about Renal Impairment is in Notes below.

Dosing for herpes simplex keratitis is based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.

How Supplied:  
  • 500 mg tablets
  • 1 g tablets

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 59° – 77°F (15° – 25°C).


VALCYTE (valganciclovir hydrochloride (450 mg) tablets)
Prescription
Oral
Tablets
Antivirals
Indications/Usage:

Indicated for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).


Typical Dosing:  

Cytomegalovirus (CMV) retinitis in adult patients:

  • Adult patients should use Valcyte tablets, not Valcyte for oral solution.
  • Valcyte tablets should be taken with food (See CLINICAL PHARMACOLOGY (12.3) in package insert).
  • For the treatment of CMV retinitis in patients with normal renal function, recommended:
    • Induction: For patients with active CMV retinitis, the recommended dosage is 900 mg (two 450 mg tablets) taken orally twice a day for 21 days.
    • Maintenance: Following induction treatment, or in adult patients with inactive CMV retinitis, the recommended dosage is 900 mg (two 450 mg tablets) taken orally once a day.
  • Additional information about Renal Impairment is in Notes below.

How Supplied:  
  • 450 mg tablets

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Excursions permitted to 59° – 86°F (15° – 30°C).


VALTREX (valacyclovir hydrochloride (500 mg; 1 g) tablets)
Prescription
Oral
Tablets
Antivirals
Indications/Usage:

For adult patients, indicated for the treatment of herpes zoster (shingles) in immunocompetent adults. The efficacy of VALTREX when initiated more than 72 hours after the onset of rash and the efficacy and safety of VALTREX for treatment of disseminated herpes zoster have not been established.

The efficacy and safety of VALTREX have not been established in patients 18 years of age with herpes zoster.


Typical Dosing:  

Herpes zoster (shingles) in immunocompetent adults, recommended:

  • 1 g 3 times daily for 7 days. Therapy should be initiated at the earliest sign or symptom of herpes zoster and is most effective when started within 48 hours of the onset of rash.

Herpes simplex keratitis (acute) in immunocompetent adults, recommended:

  • 500 mg 3 times daily for 7 – 10 days.

Herpes simplex keratitis (prophylaxis) in immunocompetent adults, recommended:

  • 500 mg daily for 1 year as prophylaxis against a simplex recurrence after recurrent bouts of keratitis.

Additional information about Renal Impairment is in Notes below.

Dosing for herpes simplex keratitis is based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.

How Supplied:  
  • 500 mg tablets
  • 1 g tablets

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 59° – 77°F (15° – 25°C).


VIBRAMYCIN (doxycycline hyclate (100 mg) capsules; doxycycline calcium (50 mg/5 mL) oral syrup; doxycycline monohydrate (25 mg/5 mL) oral suspension)
Prescription
Oral
Capsules
Oral Suspension
Antibiotics
Indications/Usage:

Indicated for the treatment of the following infections: trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence; inclusion conjunctivitis caused by Chlamydia trachomatis.

Designated gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:

  • Escherichia coli.
  • Enterobacter aerogenes.
  • Shigella species.
  • Acinetobacter species.

Consult package insert for additional information.

This medication has a broad FDA approval for the treatment of "infections due to susceptible strains of the designated microorganisms." Under our interpretation of this indication we have linked this medication with conditions we understand may be "infections due to susceptible strains of the designated microorganisms." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Trachoma or inclusion conjunctivitis caused by Chlamydia trachomatis:

  • THE USUAL DOSAGE AND FREQUENCY OF ADMINISTRATION OF DOXYCYCLINE DIFFERS FROM THAT OF THE OTHER TETRACYCLINES. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS.
  • Adults:
    • The usual dose is 200 mg on the first day of treatment (administered 100 mg every 12 hours) followed by a maintenance dose of 100 mg/day.
    • In the management of more severe infections, 100 mg every 12 hours is recommended.
    • The therapeutic antibacterial serum activity will usually persist for 24 hours following recommended dosage.
  • For children > 8 years of age:
    • The recommended dosage schedule for children with less severe disease weighing < 45 kg is 4.4 mg/kg of body weight divided into 2 doses on the first day of treatment, followed by a maintenance dose of 2.2 mg/kg of body weight given as a single daily dose or divided into twice daily doses, on subsequent days.
    • For children > 45 kg, the usual adult dose should be used.
    • The therapeutic antibacterial serum activity will usually persist for 24 hours following recommended dosage.

Recurrent corneal erosion:

  • 50 mg orally 2 times/day for 1 – 2 months.

Ocular rosacea:

  • 40 – 100 mg every day for 1 month or longer.

Additional important Dosage and Administration instructions in Notes below.

Recurrent corneal erosion and ocular rosacea typical dosing is based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.

How Supplied:  
  • Capsules (doxycycline hyclate)
    • 100 mg capsules
  • Oral syrup (doxycycline calcium)
    • 50 mg/5 mL oral syrup (473 mL bottles)
  • Oral suspension (doxycycline monohydrate)
    • 25 mg/5 mL oral suspension (60 mL bottles)

Preservatives:  

None listed in package insert (capsules); butylparaben, propylparaben, sodium metabisulfite (oral syrup); methylparaben, propylparaben (oral suspension)


Storage:  
  • Store below 86°F (30°C).
  • Store in tight, light-resistant containers.


VICODIN (hydrocodone bitartrate (5 mg; 7.5 mg; 10 mg) – acetaminophen (300 mg) tablets)
Opioid
Prescription
Oral
Tablets
Opiates/Opioids
Indications/Usage:

Indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Limitations of Use: 

Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [See WARNINGS in package insert], reserve hydrocodone bitartrate and acetaminophen tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics):

  • Have not been tolerated, or are not expected to be tolerated. 
  • Have not provided adequate analgesia, or are not expected to provide adequate analgesia.

Typical Dosing:  

Pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate:

  • Initial dosage:
    • Vicodin: 5 mg/300 mg:
      • The usual adult dosage is 1 – 2 tablets every 4 – 6 hours as needed for pain.
      • The total daily dosage should not exceed 8 tablets.
    • Vicodin ES: 7.5 mg/300 mg:
      • The usual adult dosage is 1 tablet every 4 – 6 hours as needed for pain.
      • The total daily dosage should not exceed 6 tablets.
    • Vicodin HP: 10 mg/300 mg:
      • The usual adult dosage is 1 tablet every 4 – 6 hours as needed for pain.
      • The total daily dosage should not exceed 6 tablets.
    • Conversion from other opioids:
      • There is inter-patient variability in the potency of opioid drugs and opioid formulations. Therefore, a conservative approach is advised when determining the total daily dosage of hydrocodone bitartrate and acetaminophen tablets.
      • It is safer to underestimate a patient’s 24-hour hydrocodone bitartrate and acetaminophen tablets dosage than to overestimate the 24-hour hydrocodone bitartrate and acetaminophen tablets dosage and manage an adverse reaction due to overdose.
    • Conversion to extended-release hydrocodone:
      • The relative bioavailability of hydrocodone from hydrocodone bitartrate and acetaminophen tablets compared to extended-release hydrocodone products is unknown, so conversion to extended-release products must be accompanied by close observation for signs of excessive sedation and respiratory depression.
  • Titration and maintenance of therapy:
    • Individually titrate hydrocodone bitartrate and acetaminophen tablets to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving hydrocodone bitartrate and acetaminophen tablets to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse [See WARNINGS in package insert]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.
    • If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the hydrocodone bitartrate and acetaminophen tablets dosage. If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.
  • Discontinuation:
    • When a patient who has been taking hydrocodone bitartrate and acetaminophen tablets regularly and may be physically dependent no longer requires therapy with hydrocodone bitartrate and acetaminophen tablets, taper the dose gradually, by 25% to 50% every 2 to 4 days, while monitoring carefully for signs and symptoms of withdrawal. If the patient develops these signs or symptoms, raise the dose to the previous level and taper more slowly, either by increasing the interval between decreases, decreasing the amount of change in dose, or both. Do not abruptly discontinue hydrocodone bitartrate and acetaminophen tablets in a physically-dependent patient [See WARNINGS, DRUG ABUSE AND DEPENDENCE in package insert].
  • Additional important Dosage and Administration instructions in Notes below.

How Supplied:  
  • Vicodin tablets:
    • 5/325 (5 mg hydrocodone bitartrate – 300 mg acetaminophen)
  • Vicodin ES tablets:
    • 7.5/325 (7.5 mg hydrocodone bitartrate – 300 mg acetaminophen)
  • Vicodin HP tablets:
    • 10/325 (10 mg hydrocodone bitartrate – 300 mg acetaminophen)

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).


VIGAMOX (moxifloxacin (0.5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antibiotics
Indications/Usage:

Indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species*; Micrococcus luteus*;Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus haemolyticus; Staphylococcus hominis; Staphylococcus warneri*; Streptococcus pneumoniae; Streptococcus viridans group; Acinetobacter lwoffii*; Haemophilus influenzae; Haemophilus parainfluenzae*; Chlamydia trachomatis.

*Efficacy for this organism was studied in fewer than 10 infections.


Typical Dosing:  

Bacterial conjunctivitis caused by susceptible strains of the listed organisms:

  • Instill 1 drop in the affected eye 3 times a day for 7 days.
  • For topical ophthalmic use.

►Recurrent corneal erosion:

  • Follow normal dosing patterns.

How Supplied:  
  • 3 mL bottles

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 36˚ – 77˚F (2˚ – 25˚C).


Assistance: Payment Assistance

VISINE A MULTI-ACTION EYE ALLERGY RELIEF (naphazoline hydrochloride (0.025%) – pheniramine maleate (0.3%) ophthalmic solution)
Over the Counter
Topical
Ophthalmic Solution
Ocular Decongestants/Vasoconstrictors
Indications/Usage:

Used for temporary relief of itchy, red eyes due to pollen, ragweed, grass, and/or animal hair and dander.


Typical Dosing:  

Itchy, red eyes due to pollen, ragweed, grass, and/or animal hair and dander:

  • Adults and children 6 years of age: Instill 1 – 2 drops in the affected eye(s) up to 4 times a day.
  • Children < 6 years of age:
    • Consult a doctor.

How Supplied:  
  • 15 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59° – 77°F (15° – 25°C).


VISUDYNE (verteporfin (15 mg) solution for injection)
Prescription
Injectable
IV
Other Medications
Indications/Usage:

Indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.

There is insufficient evidence to indicate VISUDYNE for the treatment of predominantly occult subfoveal CNV.


Typical Dosing:  

Predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis:

  • A course of VISUDYNE (verteporfin for injection) therapy is a 2-step process requiring administration of both drug and light.
  • The first step is the intravenous infusion of VISUDYNE. The second step is the activation of VISUDYNE with light from a nonthermal diode laser.
  • The physician should re-evaluate the patient 3 months after treatment and if choroidal neovascular leakage is detected on fluorescein angiography, therapy may be repeated.
  • Additional information on lesion size determination, spot size determination, VISUDYNE administration, light administration, and concurrent bilateral treatment is in Notes below.

How Supplied:  
  • 15 mg lyophilized cakes in single-use glass vials

Preservatives:  

None listed in package insert.


Storage:  
  • Store between 68° – 77°F (20° – 25°C).
  • Spills and disposal: Spills of VISUDYNE should be wiped up with a damp cloth. Skin and eye contact should be avoided due to the potential for photosensitivity reactions upon exposure to light. Use of rubber gloves and eye protection is recommended. All materials should be disposed of properly.
  • Accidental exposure: Because of the potential to induce photosensitivity reactions, it is important to avoid contact with the eyes and skin during preparation and administration of VISUDYNE. Any exposed person must be protected from bright light [See Warnings and Precautions (5.2) in package insert].


Assistance: Payment Assistance

Special Purchasing Instructions: How to Purchase

VORICONAZOLE (voriconazole (40 mg/mL) oral suspension; (50 mg; 200 mg) tablets; (200 mg) lyophilized powder for injectable solution)
Prescription
Ophthalmic Suspension
Oral
Tablets
Injectable
IV
Antifungals
Indications/Usage:

Indicated for use in patients 12 years of age and older in the treatment of the following fungal infections: aspergillus endophthalmitis, aspergillus keratitis, or candida endophthalmitis (with or without vitritis).

This medication is not FDA approved specifically for ophthalmic conditions. Under our interpretation of supporting peer-reviewed studies we have linked this medication with conditions we understand may benefit from off-label use of this medication. This is our medical opinion and may not be true in all clinical circumstances.

Consult package insert for additional information.


Typical Dosing:  

►Aspergillus endophthalmitis:

  • Administer 100 mcg/0.1 mL extemporaneously compounded solution intravitreally.
  • Repeat doses administered at physician discretion.
  • Concomitant systemic voriconazole therapy is also recommended.
  • Consult package insert for information on treatment of invasive aspergillosis.

►Aspergillus keratitis:

  • Apply 1 drop of extemporaneously compounded 1% ophthalmic solution topically to the cornea of the affected eye every 1 hour while awake for 1 week, then every 2 hours while awake for 2 weeks.
  • Dosing may vary.
  • Further continuation at physician discretion.

►Candida endophthalmitis, with or without vitritis, with voriconazole susceptibility:

  • Systemic therapy:
    • Administer loading dose of 400 mg (6 mg/kg) IV every 12 hours for 2 doses, then 300 mg (4 mg/kg) IV or orally every 12 hours for at least 4 – 6 weeks until resolution.
    • In patients with vitritis or with macular involvement (with or without vitritis), intravitreal therapy is also recommended.
    • Consult IV voriconazole package insert for information on preparation and administration of injectable formulation.
  • Intravitreal therapy:
    • Administer 100 mcg extemporaneously prepared in 0.1 mL sterile water or normal saline intravitreally.
    • Indicated in patients with vitritis or with macular involvement (with or without vitritis).
    • Concomitant systemic antifungal therapy is also recommended.
Dosing based on professional judgment and 2016 Infectious Diseases Society of America (IDSA) guidelines. This is our medical opinion and may not be true in all clinical circumstances.

How Supplied:  
  • Oral suspension:
    • 40 mg/mL oral suspension
  • Tablets:
    • 50 mg tablets 
    • 200 mg tablets
  • Lyophilized powder for injectable solution:
    • 200 mg vial

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Oral suspension:
    • Store at 59° – 86°F (15° – 30°C).
    • Do not refrigerate or freeze.
    • Keep the container tightly closed.
    • Discard any remaining suspension 14 days after reconstitution.
  • Tablets:
    • Store at 59° – 86°F (15° – 30°C).
  • Lyophilized powder for injectable solution:
    • Store at 68° – 77°F (20° – 25°C).
    • Following reconstitution of the lyophile with Water for Injection, the reconstituted solution should be used immediately.
    • Consult package insert for additional information.


VYZULTA (latanoprostene bunod (0.024%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Prostaglandin Analogs
Indications/Usage:

Indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Typical Dosing:  

►Elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, recommended:

  • instill 1 drop in the conjunctival sac of the affected eye(s) once daily in the evening.
  • Do not administer more than once daily since it has been shown that more frequent administration of prostaglandin analogs may lessen the IOP-lowering effect.
  • If used concomitantly with other topical ophthalmic drug products to lower IOP, administer each drug product at least 5 minutes apart.

How Supplied:  
  • 2.5 mL bottles
  • 5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Unopened bottle should be stored refrigerated at 36º – 46ºF (2º – 8ºC).
  • Once a bottle is opened it may be stored at 36º – 77ºF (2º – 25ºC) for 8 weeks.
  • Protect from light.
  • Protect from freezing.


Assistance: Payment Assistance

XALATAN (latanoprost (0.005%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Prostaglandin Analogs
Indications/Usage:

Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Typical Dosing:  

►Elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, recommended:

  • Instill 1 drop in the affected eye(s) 1 time daily in the evening. If 1 dose is missed, treatment should continue with the next dose as normal.
  • The dosage should not exceed once daily; the combined use of 2 or more prostaglandins, or prostaglandin analogs including XALATAN is not recommended. It has been shown that administration of these prostaglandin drug products more than once daily may decrease the IOP-lowering effect or cause paradoxical elevations in IOP.
  • Reduction of the IOP starts approximately 3 – 4 hours after administration and the maximum effect is reached after 8 – 12 hours.
  • May be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.
  • Contact lenses should be removed prior to the administration of XALATAN, and may be reinserted 15 minutes after administration.

How Supplied:  
  • 2.5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Protect from light.
  • Store unopened bottle(s) under refrigeration at 36° – 46°F (2° – 8°C).
  • During shipment to the patient, the bottle may be maintained at temperatures up to 104°F (40°C) for a period not exceeding 8 days.
  • Once a bottle is opened for use, it may be stored at room temperature up to 77°F (25°C) for 6 weeks.


Assistance: Payment Assistance

XELPROS (latanoprost (0.005%) ophthalmic emulsion)
Prescription
Topical
Ophthalmic Solution
Prostaglandin Analogs
Indications/Usage:

Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Typical Dosing:  

►Elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, recommended:

  • Instill 1 drop in the affected eye(s) once daily in the evening.
  • If 1 dose is missed, treatment should continue with the next dose as normal.
  • The dosage should not exceed once daily; the combined use of 2 or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. It has been shown that administration of these prostaglandin drug products more than once daily may decrease the IOP-lowering effect or cause paradoxical elevations in IOP.
  • Reduction of the IOP starts approximately 3 – 4 hours after administration and the maximum effect is reached after 8 – 12 hours.
  • May be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.
  • Contact lenses should be removed prior to the administration of XELPROS, and may be reinserted 15 minutes after administration.

How Supplied:  
  • 2.5 mL bottles

Preservatives:  

potassium sorbate


Storage:  
  • Protect from light.
  • Store at 36° – 77°F (2°C – 25°C).
  • During shipment to the patient, the bottle may be maintained at temperatures up to 104°F (40°C) for a period not exceeding 8 days.
  • After opening, XELPROS can be used until the expiration date stamped on bottle and then discarded.


Assistance: Payment Assistance

XEOMIN (incobotulinumtoxinA (50 Units; 100 Units) for injection, intramuscular use)
Prescription
Injectable
Intramuscular
Other Medications
Indications/Usage:

Indicated for the treatment of blepharospasm in adult patients.


Typical Dosing:  

Blepharospasm in adults, recommended:

  • In treatment-naive patients, the recommended Initial total dose of XEOMIN is 50 Units (25 Units per eye).
  • In ​​​​​​patients previously treated with botulinum toxin A, their ​​​​​​past dose, response to treatment, duration of effect, and adverse event history should be taken into consideration when determining the XEOMIN dose.
  • The total dose of XEOMIN should not exceed 100 Units (50 Units per eye).
  • XEOMIN is injected into the lateral and medial orbicularis oculi muscle of the upper lid; lateral canthus and the lateral orbicularis oculi muscle of the lower lid; and the corrugator muscle, if necessary (See Figure 3 in package insert). The number and location of injections may be changed in response to adverse reactions or based on the patient's response to treatment, but the total dose should not exceed 50 Units per eye.
  • The frequency of XEOMIN repeat treatments should be determined by clinical response but should generally be no more frequent than every 12 weeks [See Clinical Studies (14.4) in package insert].
  • The potency Units of XEOMIN (incobotulinumtoxinA) for injection are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of XEOMIN cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method [See Warnings and Precautions (5.2) and Description (11) in package insert]. Reconstituted Xeomin is intended for intramuscular or intra-salivary gland injection only.
  • The recommended maximum cumulative dose for any indication should not exceed 400 Units in a treatment session.
  • Additional information for Dosage and Administration is in Notes below.

How Supplied:  
  • 50 Unit single vials
  • 100 Unit single vials

Preservatives:  

None listed in package insert.


Storage:  
  • Unopened vials should be stored at or below 77°F (25°C).
  • Refrigeration of unopened vials is not required.
  • Do not use after the expiration date on the vial.
  • Reconstituted XEOMIN may be stored in a refrigerator at 36° – 46°F (2°C – 8°C) for up to 24 hours until time of use [See Dosage and Administration (2.7) in package insert].


Assistance: Payment Assistance

Special Purchasing Instructions: How to Purchase

XIIDRA (lifitegrast (5%) ophthalmic solution )
Prescription
Topical
Ophthalmic Solution
Immunosuppressants/Immunomodulators
Indications/Usage:

Indicated for the treatment of the signs and symptoms of dry eye disease.


Typical Dosing:  

►Signs and symptoms of dry eye disease:

  • Instill 1 drop twice daily (approximately 12 hours apart) into each eye using a single-use container. Discard the single-use container immediately after using in each eye.
  • Contact lenses should be removed prior to the administration of drug and may be reinserted 15 minutes following administration.

►Recurrent corneal erosion:

  • Follow normal dosing patterns.
Recurrent corneal erosion typical dosing is based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.

How Supplied:  
  • 5 single-use containers (0.2 mL each) supplied in a foil pouch.

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Store single-use containers in the original foil pouch.


Assistance: Payment Assistance

XYZAL (levocetirizine dihydrochloride (5 mg) tablets)
Over the Counter
Oral
Tablets
Antihistamines
Indications/Usage:

Used to temporarily relieve these symptoms due to hay fever or other respiratory allergies: runny nose; sneezing; itchy, watery eyes; itching of the nose or throat.


Typical Dosing:  

Symptoms due to hay fever or other respiratory allergies:

  • Adults  65 years of age:
    • Ask a doctor.
  • Adults and children 12 – 64 years of age:
    • Take 1 tablet (5 mg) once daily in the evening.
    • Do not take more than 1 tablet (5 mg) in 24 hours.
    • ½ tablet (2.5 mg) once daily in the evening may be appropriate for less severe symptoms.
  • Children 6 – 11 years of age:
    • Take ½ tablet (2.5 mg) once daily in the evening.
    • Do not take more than ½ tablet (2.5 mg) in 24 hours.
  • Children < 6 years of age:
    • Do not use.
  • Individuals with kidney disease:
    • Do not use.

How Supplied:  
  • 5 mg tablets

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 68° – 77°F (20° –  25°C).


XYZAL CHILDREN'S (levocetirizine dihydrochloride (2.5 mg/5 mL) oral solution)
Over the Counter
Oral
Oral Solution
Antihistamines
Indications/Usage:

Used to temporarily relieve these symptoms due to hay fever or other respiratory allergies: runny nose; sneezing; itchy, watery eyes; itching of the nose or throat.


Typical Dosing:  

Symptoms due to hay fever or other respiratory allergies:

  • Adults  65 years of age:
    • Ask a doctor.
  • Adults and children 12 – 64 years of age:
    • Take 5 mL or 10 mL once daily in the evening depending upon severity of symptoms.
    • Do not take more than 10 mL in 24 hours.
  • Children 6 – 11 years of age:
    • Take 5 mL once daily in the evening.
    • Do not take more than 5 mL in 24 hours.
  • Children 2 – 5 years of age:
    • Take 2.5 mL once daily in the evening.
    • Do not take more than 2.5 mL in 24 hours.
  • Children < 2 years of age:
    • Do not use. 
  • Individuals with kidney disease:
    • Do not use.

How Supplied:  
  • 2.5 mg/5 mL oral solution

Preservatives:  

methylparaben, propylparaben


Storage:  
  • Store at 68° – 77°F (20° –  25°C).


231 items found